Apoptotic and mitotic indices predict survival rates in lymph node- negative colon carcinomas

Clinical Cancer Research

Volumn 5, Issue 7, 1999, Pages 1793-1804

  Sinicrope, Frank A ^a   Hart, John ^b   Hsu, Hai An ^a   Lemoine, Michael ^a   Michelassi, Fabrizio ^b   Stephens, L Clifton ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; APOPTOSIS; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL CYCLE; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MENSTRUAL CYCLE; MIDDLE AGED; MITOTIC INDEX; PLOIDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032781795     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Hall, P. A., Coates, P. J., Ansari, B., and Hopwood, D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J. Cell Sci., 107: 3569-3577, 1994.
2. Wyllie, A. H. The biology of cell death in tumours. Anticancer Res., 5: 131-136, 1985.
3. Lin, D., Shields, M. T., Ullrich, S. J., Appella, E., and Mercer, W. E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. of the Natl. Acad. Sci. USA, 89: 9210-9214, 1998.
4. Sinicrope, F. A., Roddey, G. R., McDonnell, T. J., Shen, Y., and Stephens, L. C. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin. Cancer Res., 2: 1999-2006, 1996.
5. Moss, S. F., Liu, T. C., Petrotis, A., Hsu, T. M., Gold, L. I., and Holt, P. R. Inward growth of colonic adenomatous polyps. Gastroenterology, 111: 1425-1432, 1996.
6. Bedi, A., Pasricha, P. J., Akhtar, A. J., Barber, J. P., Bedi, G. C., Giardiello, F. M., Zehnbauer, B. A., Hamilton, S. R., and Jones, R. J. Inhibition of apoptosis during development of colorectal cancer. Cancer Res., 55: 1811-1816, 1995.
7. Hashimoto, S., Koji, T., Kahara, N., Kanematsu, T., and Nakane, P. K. Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. Virchows Arch., 431: 241-248, 1997.
8. Fielding, L. P., and Pettigrew, N. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Colorectal Cancer (Phila.) Working Group. Arch. Pathol. Lab. Med., 119: 1115-1121, 1995.
9. Witzig, T. E., Loprizini, C. L., Gonchoroff, N. J., Reiman, H. M., Cha, S. S., Weiand, H. S., Katzman, J. A., Paulsen, J. K., and Moertel, C. G. DNA ploidy and cell kinetic measurements as predictors or recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer (Phila.), 68: 879-888, 1991.
10. Bauer, K. D., Lincoln, S. T., Vera-Roman, J. W., Wallemark, C. B., Chmiel, J. S., Madurski, M. L., Murad, T., and Scarpelli, D. G. Prognostic implications of proliferative activity and DNA aneuploidy in colonic adenocarcinomas. Lab. Invest., 57: 329-335, 1987.
11. Schutte, B., Reynders, M. M., Wiggers, T., Arends, J. W., Volovics, L., Bosman, F. T., and Blijham, G. H. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res., 47: 5494-5496, 1987.
12. Scott, N. A., Wieand, H. S., Moertel, C. G., Cha, S. S., Beart, R. W., and Lieber, M. M. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma (CEA) level, and patient prognosis related to tumor DNA ploidy pattern. Arch. Surg., 122: 1375-1379, 1987.
13. Armitage, N. C., Ballantyne K. C., Evans, D. F., Clarke, P., Sheffield, J., and Hardcastle, J. D. The influence of tumor cell DNA content on survival in colorectal cancer: a detailed analysis. Br. J. Cancer, 62: 852-856, 1990.
14. Lanza, G., Gafa, R., Santini, A., Maestri, I., Dubini, A., Gilli, G., and Cavazzini, L. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study. Cancer (Phila.), 82: 49-59, 1998.
15. Collan, Y. U., Kuopio, T., Baak, J. P., Becker, R., Bogomoletz, W. V., Deverell, M., van Diest, P., van Galen, C., Gilchrist, K., Javed, A., Kosma, V. M., Kujari, H., Luzi, P., Mariuzzi, G. M., Matze, E., Montironi, R., Scarpelli, M., Sierra, D., Sisti, S., Toikkanen, S., Tosi, P., Whimster, W. F., and Wisse, E. Standardized mitotic counts in breast cancer. Evaluation of the method. Pathol. Res. Pract., 192: 931-941, 1996.
16. Lipponen, P., Papinaho, S., Eskelinen, M., Klemi, P. J., Aaltomaa, S., Kosma, V. M., Marin, S., and Syrjanen, K. DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer. Anticancer Res., 12: 1533-1538, 1992.
17. Yamasaki, F., Tokunaga, O., and Sugimori, H. Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol. Oncol., 66: 439-448, 1997.
18. Vesalainen, S., Lipponen, P., Talja, M., and Syrjanen, K. Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate, 26: 80-86, 1995.
19. Lipponen, P. K., Eskelinen, M. J., Jauhiainen, K., Harju, E., Terho, R., and Haapasalo, H. Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int. J. Cancer, 51: 396-403, 1992.
20. Cooper, G. S., Yuan, Z., Landefeld, C. S., Johanson, J. F., and Rimm, A. A. A national population-based study of incidence of colorectal cancer and age. Implications for screening in older Americans. Cancer (Phila.), 75: 775-781, 1995.
21. Loffeld, R., Putten, A., and Balk, A. Changes in the localization of colorectal cancer: implications for clinical practice. J. Gastroenterol. Hepatol., 11: 47-50, 1996.
22. Brievik, J., Meling, G. I., Spurkland, A., Rognum, T. O., and Daudernack, G. K-ras mutation in colorectal cancer: relations to patients age, sex and tumour location. Br. J. Cancer, 69: 367-371, 1994.
23. Elnatan, J., Goh, H. S., and Smith, D. R. C-KI-RAS activation and the biological behavior of proximal and distal colonic adenocarcinomas. Eur. J. Cancer, 32A: 491-497, 1996.
24. Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remvikos, Y., Girodet, J., Salmon, R. J., and Thomas, G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106: 42-48, 194.
25. Auvinen, A., Isola, J., Visakorpi, T., Koivula, T., Virtanen, S., and Hakama, M. Overexpression of p53 and long term survival in colon carcinoma. Br. J. Cancer, 70: 293-296, 1994.
26. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A., Stemmerman, G., Wells, J. D., MacDonald, J. S., and Meyskens, F. L. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group Study. Cancer Res., 58: 1149-1158, 1998.
27. Morrin, M., Kelly, M., Barrett, N., and Delaney, P. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut, 35: 1627-1631, 1994.
28. Waldman, T., Kinzler, K. W., and Vogelstein, B. p21 is necessary for the p53-mediated GI arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
29. Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., and Van Dyke, T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78: 703-711, 1994.
30. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
31. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood, 88: 386-401, 1996.
32. Hockenberry, D. M., Zutter, M., Hickley, W., Nahm, M., and Korsmeyer, S. J. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA, 88: 6961-6965, 1991.
33. Sinicrope, F. A., Ruan, S., Cleary, K. R., Lee, J. J., and Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res., 55; 237-241, 1995.
34. Hague, A., Moorghren, M., Hicks, D., Chapman, M., and Paraskeva, C. Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene, 9: 3367-3370, 1994.
35. Ofner, D., Riehemann, K., Maier, H., Riedmann, B., Nehoda, H., Totsch, M., Bocker W., Jasani, B., and Schmid, K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br. J. Cancer, 72: 981-985, 1995.
36. Manne, U., Myers, R. B., Moron, C., Poczatek, R. B., Dillard, S., Weiss, H., Brown, D., Srivastava, S., and Grizzle, W. E. Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int. J. Cancer, 74: 346-358, 1997.
37. Baretton, G. B., Diebold, J., Christoforis, G., Vogt, M., Muller, C., Dopfer, K., Schneiderbanger, K., Schmidt, M., and Lors, U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer (Phila.), 77: 255-264, 1996.
38. Sinicrope, F. A., Hart, J., Michelassi, F., and Lee, J. J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res., 1: 1103-1110, 1995.
39. Bosari, S., Moneghini, L., Graziani, D., Lee, A. K., and Murray, J. J. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum. Pathol., 26: 534-540, 1995.
40. Moertel, C. G., Fleming, T. R., MacDonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., and Glick, J. H. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Duke's B2 colon cancer. J. Clin. Oncol., 13: 2936-2943, 1995.
41. Beahrs, O. H., Hensen, D. E., Hutter, R. V., and Myers, M. H. (eds). American Joint Commission on Cancer: Manual for Staging of Cancer, Ed. 3. Philadelphia: J. B. Lippincott, 1998.
42. Meyn, R. E., Stephens, L. C., Hunter, N. R., and Milas, L. Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs. 6: 443-450, 1995.
43. Hedley, D. W., Friedlander, M. S., Taylor, I. W., Rugg, C. A., and Musgrove, E. A. Methods for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 31: 1333-1335, 1983.
44. Baisch, H., Beck, H. P., Christensen, I. J., Hartmann, N. R., Fried, J., Dean, P. N., Gray, J. W., Jett, J. H., Johnston, D. A., White, R. A., Nicolini, C., Zeitz, S., and Watson, J. V. A comparison of mathematical methods for the analysis of DNA histograms obtained by flow cytometry. Cell Tissue Kinet., 15: 235-249, 1982.
45. Hiddemann, W., Schumann, J., Andreef, M., Barlogie, B., Herman, C. J., Leif, R. C., Mayall, R. H., Murphy, R. F., and Sandberg, A. A. Convention on nomenclature for DNA cytometry. Cancer Genet. Cytogenet., 13: 181-183, 1984.
46. Silvestrini, R., Veneroni, S., Daidone, M. G., Beini, E., Boracchi, P., Mezzetti, M., DiFronzo, G., Rilke, F., and Veronesi, U. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499-504, 1994.
47. Bennett, S. Log-logistic regression models for survival data. Appl. Stat., 32: 165-171, 1983.
48. Tannapfel, A., Hahn, H. A., Katalinic, A., Fietkau, R. J., Kuhn, R., and Wittekind, C. W. Incidence of apoptosis, cell proliferation and p53 expression in renal cell carcinomas. Anticancer Res., 17: 1155-1162, 1997.
49. Remvikos, Y., Laurent-Puig, P., Salmon, R. J., Frelat, G., Dutrillaux, B., and Thomas, G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int. J. Cancer, 45: 450-456, 1990.
50. Offerhaus, G. J. A., De Feyter, E. P., Cornelisse, C. J., Tersmette, K. W. F., Floyd, J., Kern, S. E., Vogelstein, B., and Hamilton, S. R. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology, 102: 1612-1619, 1992.
51. Joensuu, H., Pylkkanen, L., and Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.
52. Berardo, M. D., Elledge, R. M., de Moor, C., Clark, G. M., Osborne, C. K., and Allfred, D. B. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer (Phila.), 82: 1296-1302, 1998.
53. Langlois, N. E., Lamb, J., Eremin, O., and Heys, S. D. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products. J. Pathol., 182: 392-397, 1997.
54. Jansson, A., and Sun, X. F. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. Acta Pathol. Microbiol. Immunol. Scand., 105: 730-734, 1997.
55. Rich, T. A., Sinicrope, F., Stephens, C., Meyn, R., Terry, N., Meistrich, M., Skibber, J., Ajani, J., Cleary, K., and Lynch, P. Down-staging of T3 rectal cancer after preoperative infusional chemoradiation is correlated with spontaneous apoptosis index and Bcl-2 staining. Int. J. Radiat. Oncol. Biol. Phys., 36: 259, 1996
56. Milross, C. G., Mason, K. A., Hunter, N. R., Chung, W. K., Peters, L. J., and Milas, L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst., 88: 1308-1314, 1996.
57. Meyn, R. E., Stephens, L. C., Ang, K. K., Hunter, N. R., Brock, W. A., Milas, L., and Peters, L. J. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int. J. Radiat. Biol., 64: 583-591, 1993.
58. Steinberg, S. M., Barkin, J. S., Kaplan, R. S., and Stablein, D. M. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer (Phila.), 57: 1866-1870, 1986.
59. Carder, P. J., Cripps, K. J., Morris, R., Collins, S., White, S., Bird, C. C., and Wyllie, A. H. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br. J. Cancer, 71: 215-218, 1995.
60. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington DC), 267: 1353-1356, 1995.
61. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S., and Vande Woude, G. F. Abnormal centrosome amplification in the absence of p53. Science (Washington DC), 271: 1744-1747, 1996.
62. Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., and Quirke, P. Prognostic value of p53 overexpression and c-ki-ras gene mutations in colorectal cancer. Gastroenterology, 104: 57-64, 1993.
63. Dix, B., Robbins, P., Carello, S., House, A., and Iacopetta, B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br. J. Cancer, 70: 585-590, 1994.
64. Cripps, K. J., Purdie, C. A., Carder, P. J., White, S., Komine, K., Bird, C. C., and Wyllie, A. H. A study of stabilisation of p53 protein versus point mutations in colorectal carcinoma. Oncogene, 9: 2739-2743, 1994.
65. Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Vogelstein, B., and Hamilton, S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172: 5-12, 1994.
66. Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Muraoka, M., Onda, A., Okumura, Y., Kishi, N., Iwama, T., Mori, T., Koike, M., Ushio, K., Chiba, M., Nomizu, S., Konishi, F., Utsunomiya, J., and Miyaki, M. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology, 111: 307-317, 1996.
67. Lothe, R. A., Peltomaki, P., Meling, G. I., Aaltonen, L. A., Nyström-Lahti, M., Pylkkanen, L., Heimdal, K., Anderson, T. I., Møller, P., Rognum, T. O., Fosså, S. D., Haldorsen, T., Langmark, F., Brøgger, A., de la Chapelle, A., and Børresen, A-L. Genomic instability in colorectal cancer: relationship of clinicopathological variables and family history. Cancer Res., 53: 5849-5852, 1993.
68. Sankila, R., Aaltonen, L. A., Jarvinen, H. J., and Mecklin, J. P. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology, 110: 682-687, 1996.
69. WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin. Cancer Res., 4: 1251-1261, 1998.
70. Thibodeau, S. N., Bren, G., and Schaid, D. Microsatellite instability in cancer of the proximal colon. Science (Washington DC), 260: 816-819, 1993.
71. Watson, A. J., Merritt, A. J., Jones, L. S., Askew, J. N., Anderson, E., Becciolini, A., Balzi, M., Potten, C. S., and Hickman, J. A. Evidence of reciprocity of Bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br. J. Cancer, 73: 889-895, 1996.
72. Winter, N. J., Anderson, J., Reed, J. C., Krajewski, S., Variakojis, D., Bauer, K. D., Fisher, R. I., Gordon, L. I., Oken, M. M., Jiang, S., Jeffries, D., and Domer, P. Bcl-2 expression correlates with clinical proliferative activity in the intermediate-and high-grade, non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood, 91: 1391-1398, 1998.
73. Borner, C. Diminished cell proliferation associated with the death protective activity of bcl-2. J. Biol. Chem., 271: 12695-12698, 1996.
74. O'Reilly, L. A., Huang, D. C., and Strasser, A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J., 15: 6979-6990, 1996.
75. O'Reilly, L. A., Harris, A. W., Tarlinton, D. M., Corcoran, L. M., and Strasser, A. Expression of a bcl-2 transgene reduced proliferation and slows turnover of developing B lymphocytes in vivo. J. Immunol., 159: 2301-2311, 1997.
76. Pietenpol, J. A., Papadopoulos, N., Markowitz, S., Wilson, J. K., Kinzler, K. W., and Vogelstein, B. Paradoxical inhibition of solid tumor growth by bcl-2. Cancer Res., 54: 3714-3717, 1994.
77. Huang, D. C., O'Reilly, L. A., Strasser, A., and Cory, S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J., 16: 4628-4638, 1997.